Biotech Values

[gofishmarko]

>> What do you see as the pros and cons of the CTP approach relative to the PEGylation approach for producing next-generation versions of protein drugs? <<


I haven't really looked into it but maybe I will since it is an interesting question.

I know that some proteins don't seem to PEGylate well , for whatever reasons. If you assume that CTP proteins would be manufactured using some recombinant-based method , you have the advantage that you end up with a finished product , instead of one that needs to be PEGylated in a separate step.

The CTP approach might be useful for things like peptide- based protease inhibitors where half-life of the peptide is a limiting factor and where having a big PEG molecule flopping around might interfere with binding to the active site.